glp-1 drugs and menopause What I Got Wrong About Metabolism—and What I Recommend Now GLP-1 Weight-Loss Drugs and Menopause:

In humans, nearly all circulating GLP-1 is one of the truncated forms, with 80% of GLP-1 immunoreactivity corresponding to GLP-1 (7-36amide) and 20% to the glycine-extended GLP-1 (737) [175]

Other research highlights: 30% of GLP-1 users tested positive for SIBO or IMO even after accounting for diabetes (5) GLP-1 medicines caused microbiome changes and altered metabolism in mice (6) GLP-1 medicines tested in humans only had noticeable microbiome changes by 48 weeks (7) Despite not necessarily having slower gut motility, one study found that 88.9% of obese patients had SIBO (8) A meta analysis of people with IBS symptoms, found that up to 78% of people had SIBO, many of whom were undiagnosed (9) Overall, Sun and colleagues (1) could not prove a mechanistic link between GLP-1 medications and SIBO, however they did find that SIBO was twice as likely in GLP-1 users

doi: 10.1006/geno.1995.9937

G.VenemaK.van de PollM

The involvement of GLP-1 in PD can be simplified to the activation of the MAPK/extracellular signal-regulated kinase 1/2 (ERK) pathway, which has an important role in synaptic plasticity, and the PI3K/Akt pathway signaled by GLP-1 receptor stimulation and the subsequent increase in cAMP and PKA and PI3K activation [73]

Readers who want to verify current plan terms can review current Gala Health GLP-1 pricing and eligibility details here